

---

## Dasatinib or High-dose Imatinib for Chronic-phase Chronic Myeloid Leukemia After Failure of First-line Imatinib: a Randomized Phase 2 Trial

HAGOP KANTARJIAN, RICARDO PASQUINI, NELSON HAMERSCHLAK, PHILIPPE ROUSSELOT, JERZY HOLOWIECKI, SAENGSUREE JOOTAR, TADEUSZ ROBAK, NINA KHOROSHKO, TAMAS MASSZI, ALEKSANDER SKOTNICKI, ANDRZEJ HELLMANN, ANDREY ZARITSKY, ANATOLY GOLENKOV, JERALD RADICH, TIMOTHY HUGHES, ATHENA COUNTOURIOTIS, AND NEIL SHAH. *BLOOD*. 2007 JUN 15;109(12):5143-50.

---

Present study<sup>8</sup> is a randomized, international, open-label, phase II study conducted in CML-CP patients, with primary or acquired resistance to conventional doses of imatinib. Patients were randomized 2:1 to 140 mg dasatinib (n = 101) or 800 mg imatinib (n = 49). Patients were of at least 18 years of age and had adequate organ functions. All patients were dasatinib-naïve. To avoid potential bias, patients with known specific BCR-ABL mutations with high resistance to imatinib were excluded. Treatment differences were analyzed retrospectively using the Agresti-Min exact test, and Time to treatment failure was analyzed using Kaplan-Meier method and an unstratified log rank test. The hazard ratio was computed using a Cox proportional hazard model.

Complete hematologic responses (CHR) were observed in 93% and 82% of patients receiving dasatinib and high-dose imatinib (P = .034), respectively. Dasatinib resulted in higher major cytogenetic response rates (MCR) (52%) than high-dose imatinib (33%) (P = .023); this included complete cytogenetic response (CCR) in 40% and 16% (P = .004). The degree of improvement in cytogenetic response from baseline (ie, no response to MCyR) was 3-fold higher, as well as responses were more durable for patients receiving dasatinib. Major molecular responses (MMR) were also more frequent with dasatinib (16% versus 4%; P = 0.038). Treatment failure (hazard ratio [HR], 0.16; P < .001) and progression-free survival (HR, 0.14; P < .001) both favored dasatinib.

Superficial edema (42% versus 15%) and fluid retention (45% versus 30%) were more common in imatinib group while pleural effusion was more common with dasatinib (17% versus 0%). Pleural effusions were successfully managed with dasatinib dose interruption, diuretics, and/or pulse steroid therapy. Grade 3 to 4 non hematologic toxicity was minimal. Cytopenias were more common and more severe in the dasatinib treatment group (grade 3-4

(33%) required dose interruptions while dose reduction was done in 5 patients (10%).

### Comments

Results of the current study<sup>8</sup> suggest that dasatinib is more effective than high-dose imatinib in this Imatinib resistant CML-CP population. With a median follow up of 15 months, progression-free survival was

**Table I. Studies on the treatment of patients with imatinib resistance using Dasatinib**

Author	CML Phase	n	Haematological Response	Cytogenic Response	Grade II-IV toxicity (%)
George et al <sup>10</sup>	MBC LBC	74 42	MHR- (34) -(31)	MCR- (31) - (50) CCR-(86)	diarrhoea(36& 31), Pleural effusion (28&14) pyrexia (16&19), nausea (16&24), vomiting (16&24)
Talpaz et al <sup>11</sup>	CP AP/BC ph+All	40 44	CHR 37/40 MHR 31/44	(45) (25)	Neutropenia, Pleural effusion, oedema, headache
Talpaz et al <sup>12</sup> START-A study	AP	107 evaluable	MHR 63 (59) CHR 35 (33) no evi of leukemia 28 (26)	MCR 33 (32) CHR 23 (22) PHR 10 (10)	Thrombocytopenia (79), neutropenia (69), diarrhea (46), oedema (27) Pleural effusion (16), rashes (8), gastrontestinal bleed (7)
Coutre et al <sup>13</sup> START-L study	L-BC Ph+ALL	42 36	MHR (31) CHR (26) MHR (42) CHR (31)	MCR (50) MCR (58)	Thrombocytopenia (82), neutropenia (76), diarrhea (30), Pleural effusion (13), rashes (17), nausea (23), fatigue (19)
Estrov et al <sup>14</sup>	Nilotinib failed CML	CP 1 AP 5 BC 5 2 <sup>nd</sup> CP 1	CHR 1/1 CHR 4/5 CP 1, BMCR 1	Not given	Not given
Cortes et al <sup>15</sup> START-B study	M-BC	74	HR 39(53) MHR 24 (32) CHR 18 (24) No leukemia 6 (8)	MCR 22 (32) CCR 20 (27)	diarrhoea(7), Pleural effusion (9), rashes (11), nausea (4), oedema (14)

(Values in parentheses are percentages, CP chronic phase, AP-accelerated phase, BC blast crisis, L-BC-lymphoid blast crisis, HR-haematological response)

neutropenia: 61% versus 39%; grade 3-4 thrombocytopenia: 56% versus 14%); these were reversible and manageable with dose adjustments. Dose interruptions were required in 84 patients (83%) receiving dasatinib therapy (primarily due to hematologic toxicity [61%]), dose reductions were noted in 67 patients (66%), and dose escalations were made for 33 patients (33%). In high-dose imatinib group, 16 patients

significantly prolonged. Rates of major cytogenetic responses (including a >2-fold increase in complete CGR), favored dasatinib. In patients with no prior cytogenetic response to the conventional doses of imatinib, high-dose imatinib was also ineffective. But even in these, 50% achieved a major cytogenetic responses with dasatinib. Dasatinib was clearly superior in patients who failed or progressed on Imatinib

600 mg per day. But in subgroups only minimally resistant to imatinib like those failed or progressed on 400 mg imatinib per day, little difference was noted. Cytogenetic responses were more rapid for patients receiving dasatinib than for high dose (HD) imatinib (with complete cytogenetic response rates of 40% and 16%, respectively).

The toxicity profile seen for dasatinib group was similar to previous studies, but there are differences between dasatinib and HD imatinib group. Dasatinib was associated with a greater degree of myelosuppression, (mainly thrombocytopenia), possibly due to rapid clearance of BCR-ABL expressing malignant hematopoietic cells. Other explanation could be that, unlike imatinib, dasatinib is not a substrate of the p-glycoprotein pump, and therefore higher concentrations of dasatinib might be achieved in hematopoietic progenitor cells. In patients who experienced myelosuppression, recovery occurred after brief dose interruptions or reductions, occasionally requiring transfusions. Fluid retention was more common with imatinib, presented as superficial edema in imatinib and pleural effusion in dasatinib group. Dasatinib was associated with a significant prolongation in the time to treatment failure.

Dasatinib is a potent inhibitor of SRC/ABL kinase inhibitor. Dasatinib's ability to overcome different forms of imatinib resistance is other possible mechanism. The only *BCR-ABL* mutation resistant to dasatinib in the current study is the ATP binding site mutation T315I<sup>5</sup>. Recent crystal structure studies suggest that dasatinib may be more effective in the P-loop resistance (to imatinib).<sup>9</sup> Table-1 provides review of previous studies with use of dasatinib in imatinib resistant patients.

Thus, data from above two studies suggest that Dasatinib represents a safe and effective therapy for CP-CML patients resistant to

conventional imatinib doses with improved cytogenetic and molecular response rates and progression-free survival relative to high-dose imatinib. Dasatinib is also effective in patients with accelerated phase of CML. With the incidence of imatinib resistance increasing, the earlier use of dasatinib could prove beneficial by promoting an early response, and thereby potentially improving the prognosis for the patient, and/or by avoiding the development of treatment resistance.<sup>16</sup>

#### REFERENCES:

1. Bhutani M, Kumar L, Kochupillai V. *Lympho-hemopoietic malignancies in India. Med Oncology* 2002;19:141-150
2. Kumar L. *Chronic Myelogenous leukemia (CML): An update. Nat Med J India* 2006;19:255-63
3. Druker BJ, Guilhot F, O'Brien S, et al. *Five year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Engl J Med.* 2006;355:2408-2417.
4. Mauro M, Deininger M. *Chronic myeloid leukemia in 2006: a perspective. Hematologica.* 2006;91:152-158.
5. Shah NP. *Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program.* 2005:183-187.
6. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. *Overriding imatinib resistance with a novel ABL kinase inhibitor. Science.* 2004;305:399-401.
7. Guilhot F, Apperley J, Kim D et al. *Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood* 2007 May 15;109(10):4143-50.
8. Kantarjian H, Pasquini R, Hamerschlak N, et al. *Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood.* 2007 Jun 15;109(12):5143-50.
9. Tokarski J, Newitt J, Lee F, et al. *The crystal structure of Abl kinase with BMS-354825, a dual SRC/ABL kinase inhibitor. Blood.* 2004;104:abstract 553
10. Cortes J, Rousselot Ph, Kim D et al. *Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood.* 2007;109:3207-3213
11. Talpaz M, Shah NP, Kantarjian H, et al. *Dasatinib in imatinib resistant CML and Philadelphia chromosome positive leukemias. NEJM* 2006;354:2531-41

12. *Talpaz M, Apperley J. F., Kim D. W., et al. Dasatinib in patients with AP-CML who are resistant or intolerant to Cmatinib:results of the CA180005 'START-A'study.Proc Am Soc Clin Oncol 2006;24:343a(Abstract 6526).*
13. *Coutre S., Martinelli G., Dombret H. , et al . Dasatinib in patients with LB- CMLor Ph +ALL who are imatinib resistant or intolerant:the CA180015 'START- L' study. Proc Am Soc Clin Oncol 2006;24:6528.*
14. *Estrov Z. , O'Brien S., Giles F., et al. Dasatinib, a dual Src- abl inhibitor, is active in Ph +CML following treatment with imatinib and AMN107. Proc Am Soc Clin Oncol 2006;24:344a (abstract 6530)*
15. *Cortes J. E., Kim D. W., Rosti G., et al. Dasatinib in patients with CML- MBC who are imatinib resistant or intolerant: Results of the CA180006 'START- B' study. Proc Am Soc Clin Oncol 2006; 24:6529.*
16. *Kantarjian H, O'Brien S, Talpaz M, et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer. 2007;15;109(8):1556-60*

**Jyoti Bajpai**

Department of Medical Oncology  
BRA Institute Rotary Cancer Hospital  
All India Institute of Medical Sciences  
New Delhi 110029  
E Mail : dr\_jyotibajpai@yahoo.co.in

